In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."
More from Investing
The top holder in several companies, the hedge fund's abrupt liquidation has contributed to weakness.
You've probably been told timing the market is futile, but here's a way to make it possible -- if you're willing to do the work.
Along with the media proclamation of a bear market, we have some improvement in the charts of many smaller stocks, but ...